Hello, good afternoon. My name is Olivia Talman. I am the CEO of NXOA. Who is Nikua? Nikua is a Belgium tech company that is offering an innovative solution to treat or to introduce the next generation of stimulation to treat obstructive sleep apnnea. We are a public company. We are listed on both NASDAQ and also Euronex Brussels. And since recently to be precise, August 8th was a phenomenal day in the company history because we obtained FDA approval and the team is currently launching in the US. I will come back in my presentation why the US launch is so important. Now going to the next slide as you can see our vision is make sleep simple. What we will what we mean with making sleep simple is the fact that everything we do should be focused around the patient. We want to make sure that we not only offer an efficient technology also a safe technology and in the translation in the surgical approach that we are using I hope that I will be able to clarify during the next slides. Now if you look at the blueprint for our success and why we believe that we will be successful there are three key pillars. One starts with the market. The market of obstructive sleep apnnea is a huge market. It's currently also a market that is a lot under media attention. Goes from diagnosis all the way to treatment options and of course the management of patients once they have obtained their treatment. To throw some numbers at you when we talk about the huge market in the US we are talking about 400,000 patients that are suffering from moderate to severe OSA and that would be eligible for the genior solution. There are many more patients suffering from mild OSA but we are focused on the on the group of moderate to severe that is express that that is expressed by the number of obstructions that they are having and it starts by having minimum 15 and it can go all the way up to over 30 40 50 obstructions every hour when you sleep. Now the reason why we treat obstructive sleep apnnea is pretty straightforward. Each time you have an airway obstruction there is a lack of oxygen. A lack of oxygen means also an increased risk for cardiovascular diseases that goes up by five and your risk for stroke also doubles. Now looking at the market 400,000 patients that could be treated in the US. If you look at Europe that is more or less comparable number and it's up to 300,000. If you put some financials behind in pharma they would say this is a blockbuster potential because the market is over 10 billion. No, today instead of $10 billion the market is reaching $1 billion already and if we look back five years ago there was no market. Hypoglossal nerve stimulation or neuro stimulation was simply not truly existing or only capturing a very tight number of those patients. So it's an extreme fast growing market. If we look at the 1 billion how it spread geographically and here you will understand where why we are so proud of the of the FDA approval is that 950 million out of the 1 billion market is generated in the US and 50 million is coming from outside US I prefer saying from the international markets mainly Europe and also the beginning of some Asian markets. Now the next or the second pillar in a successful launch is you need someone who will pay for your technology. If you look at the US, their hyposal nerve stimulation is covered. It's well covered. Over 280 million lives or secure or insured lives of people who are suffering from OSA will have a full reimbursement for their technology. It's covered by the government, Medicare and the local max, but it's also covered of course by commercial payers. If we look in Europe, it's a more fragmented market. We go country by country. We are currently active already in Germany. That is our large largest market. We recently opened also the UK and we were envisioning some other markets like the banal Belgium Netherlands. Belgium being our home country where it all started. We look at the Netherlands and we're also looking entering Singapore in a relatively short period of time. So from a coverage perspective I think we're also the risk where we are doing well. We have our CPT code in the US and in the country that I just mentioned in Europe we also have a full reimbursement code. Then we're going to I think the most important topic and that is the technology. How can you create and how can you have a disruptive technology? I will not go too technical. I like to talk patience because in our vision making sleep simple I do believe that when you are an obstructive sleepa patient you should not feel as a patient. So in the genius solution you have two components. One will be the implantable component that you can see in the in the little square. So it's a very simple passive implant. [snorts] It's an incision under the chin made by ENT surgeons. The surgery takes less than 60 minutes. We have seen surgeons doing it already in 30 minutes. And once you have an implant, you also have an implant for life. So we do have a longevity of 25 years for a device. And once it implanted, the patient can also not see the implant. You cannot feel the implant. And I think also because it's a passive implant, we can guarantee full body MRI compatibility from the get-go. And that is also something that is again supporting making sleep simple. You don't need to worry when you have an implant. The next advantage of the technology is that there is no battery that is implanted in your body. Currently in the market of hyperosal nerve stimulation, there is one company that owns the monopoly. They have a pacemaker solution. We believe in our vision that to treat OSA you should become minimum invasive one incision no battery implanted an implant for life. Now the next thing and I'm just moving a little bit slides you can see that the lady and the gentleman were wearing something under their chin that is what we call the re the wearable component. The wearable component is containing two things. one the battery and we transfer energy through induction activating the passive device that is implanted and next it's also containing the software or the brains of the system. Now what is the big advantage when you have an external software an external brain of your system? You actually don't need a patient. If you want to upgrade something the moment you have access to the wearable component being it a physician being it the patient itself that can also in fact play a little bit with with with the parameters and find their optimal comfort. This all can be done without the need again for resurgery. And I think this is again crucial in illustrating how we want to make sleep simple. Give you a concrete example. We recently launched a software upgrade. We pushed it through a little bit comparable like you get with your phones. You say there is a software upgrade available. The patient is logging in with a variable component through the computer and the software uh was upgraded automatically. Next in going forward if we would come with a different shape of variable component also there there is no need to replace the implantable component you can simply upgrade this and in our concept of an implant for life in making sleep simple in being patient centered those are big differentiation factors or major differentiation factors compared to what is currently out there in the morning what happens of course you remove your dis disposable patch you put your wearable in the charging unit. As you can see, you open your phone and [clears throat] that is the next one. And you get an app where you get some basic information on your sleep quality. Again, supporting making sleep simple and also providing ownership and also a kind of commitment with the patient that when you use it correct, you can see the results, you will feel better, you will be well rested, you will be able to return to work, and you're also protected I for with a decreased mortality risk. So that is in a nutshell what we are doing. I would like to come back to where I started. Why do we believe we will be successful? We are launching in the largest market currently in the US. If you look at our sales model over there, we are doing this direct. We have a sales force of over 50 people already actively in the field. We will scale up in a gradual way. Every quarter we will open new centers by adding more territory managers. We are focused on the high volume implant sites. Next to this, the referral part crucial in our opinion. So we're looking at sleep providers as they called in the US. I prefer saying sleep physicians. Most of the time they are primologists that are managing patients that are prescribing CPOP. We know that there are a lot of patients that don't like the mask or cannot tolerate the mask over time. But when they are in need because of their condition and severity being moderate to severe OSA patient then we do believe that go is the correct solution for them in going forward. We are educating sleep doctors as well. What is their role postsurgery management? How do they follow up the patient? We teach them how to in fact manage go and understand what stimulation does. We teach them how to stimulate themsel, change some parameters always to find the optimal comfort for the patient and the optimal outcome. And next to this, we also use them to gather data by introducing home sleep test that can be used on regular base three six months to evaluate to further motivate the patient to provide us with feedback that we can also incorporate and learn further and of course also to build the first health economic data. Last comments and the last minutes I will use is also how do we see the future. Today we have the implantable component that is already an implant for life. There is the wearable. In going forward we are investing heavily in also getting rid of the wearable and having a full system with no wearables attached just the implant. We call it the pillow charging aspect. You would sleep put your head on a pillow during while you were doing this. There would be a power source on your nightstand. we create a closed loop and you would not even realize or not even have to think as an OSA patient. This is not scient science fiction. It's something that is already existing in different aspects in different technologies. We try to combine this again to make sure that once you have your implant you can sleep on your back in a in a supine position. You can sleep on your side. You can have more complex airway obstructions like complete concentric collapse with Geno. you know that you will be protected and that your airway will maintain open during the entire night and we see this as the future in going forward. Thank you for your attention and it was a pleasure being here. Thank you.